Mumbai: Once bitten twice shy? Not in the case of Venkat Jasti, chairman and CEO of Suven Life Sciences, who is gearing up to conduct Phase-3 clinical trials of a potential therapy against Alzheimer's disease despite its partial failure in Phase-2 study.
Our Bureau, Mumbai, Tuesday, August 17, 2021, 13:00 Hrs [IST]nSuven Life Sciences announced that NCE SUVN-502 (masupirdine), a potent, selective, brain penetrant and orally active, novel chemical entity has planned initiation of global phase 3 clinical trial for the treatment of agitation and aggression in Alzheimer's type dementias with expected enrollment of patients from middle of September 2021.
Amassive fire has been reported at a pharma research and manufacturing company in Telangana's Hyderabad.
Suven Life Sciences Generic Calcium Acetate Receives Approval In US
The new report offers a powerful combination of latest, in-depth research studies on the Scopolamine market. The authors of the report are highly experienced analysts and possess deep market knowledge. Some of the key players operating in this Report are: Alkaloids of Australia, Centroflora-cms, Phytex Australia, Alchem International, Guangzhou Hanfang, Alkaloids Corporation, Luyin, Fine Chemicals Corporatio
Suven Life Sciences share price was locked at 5 percent upper circuit after the company's promoters were reportedly looking to sell their CRAMS business.
Indian pharmaceutical company Suven Life Sciences has failed to meet the primary endpoint in its Phase IIA proof-of-concept study that evaluated the efficacy, safety and tolerability of masupirdine (SUVN-502) for the treatment moderate Alzheimer’s disease.
The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder, Huntington's disease, Parkinson's and schizophrenia, it added.
In ‘stalking horse’ asset purchase pact with Aceto of U.S.
Biopharmaceutical firm Suven LifeNSE -0.45 % Sciences Ltd on Friday said it has entered into an asset purchase agreement to buy the assets of US-based Aceto Corporation's Rising Pharmaceuticals through its joint venture partner Shore Suven Pharma Inc.